新诊断心血管疾病或心力衰竭的医保老年人中GLP-1受体激动剂与SGLT2抑制剂早期使用的不足与差异
研究基于2016-2019年医保数据,纳入4,057,725例65岁以上2型糖尿病合并新发动脉粥样硬化性心血管疾病或充血性心力衰竭的患者,分析GLP-1受体激动剂或SGLT2抑制剂180天内启动的种族/民族及社会经济剥夺差异。结果显示启动率在所有年份均低(<0.6次/100人月),黑人及其他种族/民族启动率较低,社会经济剥夺指数越高启动率越低。
要点
- 所有年份GLP-1受体激动剂或SGLT2抑制剂启动率均低(<0.6次/100人月)。
- 黑人(HR 0.81)及其他种族/民族(HR 0.84)启动率低于参照组。
- 社会经济剥夺指数每增加1单位,启动风险降低(HR 0.96)。
核心结论
- 在合并动脉粥样硬化性心血管疾病或充血性心力衰竭的老年2型糖尿病患者中,GLP-1受体激动剂或SGLT2抑制剂启动率低,提示指南推荐治疗的提供存在重大不足或治疗障碍。
- 黑人及其他种族/民族个体以及地区层面社会经济剥夺程度较高者启动这些药物的可能性更低。
研究设计与样本
- 使用2016-2019年医保数据,识别4,057,725例年龄>65岁、患有2型糖尿病且新发动脉粥样硬化性心血管疾病或充血性心力衰竭的个体。
- 采用校正Cox比例风险模型,按种族/民族和邮政编码层面社会剥夺指数估计180天内GLP-1受体激动剂或SGLT2抑制剂启动的发生率及风险比(HR)。
主要发现
- GLP-1受体激动剂或SGLT2抑制剂启动的发生率随时间增加,但在所有研究年份均低(<0.6次/100人月)。
- 黑人个体启动风险低于参照组(HR 0.81 [95% CI 0.79-0.84]),其他种族/民族个体启动风险亦低于参照组(HR 0.84 [95% CI 0.75-0.95])。
- 启动风险随社会剥夺指数增加而降低(HR 0.96 [95% CI 0.96-0.97])。
- 动脉粥样硬化性心血管疾病患者的启动率高于充血性心力衰竭患者(0.35 vs. 0.135次/100人月)。
- 中度合并症(如肾病、非酒精性脂肪性肝病)与较高的启动概率相关,而重度合并症(如晚期慢性肾脏病、肝硬化)与启动概率无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the association of race/ethnicity and socioeconomic deprivation with initiation of guideline-recommended diabetes medications with cardiovascular benefit (glucagon-like peptide 1 receptor agonists [GLP1-RA] and sodium-glucose cotransporter 2 inhibitors [SGLT2i]) among older adults with type 2 diabetes (T2D) and either incident atherosclerotic cardiovascular disease (ASCVD) or congestive heart failure (CHF). RESEARCH DESIGN AND METHODS: Using Medicare data (2016-2019), we identified 4,057,725 individuals age >65 years with T2D and either incident ASCVD or CHF. We estimated incidence rates and hazard ratios (HR) of GLP1-RA or SGLT2i initiation within 180 days by race/ethnicity and zip code-level Social Deprivation Index (SDI) using adjusted Cox proportional hazards models. RESULTS: Incidence rates of GLP1-RA or SGLT2i initiation increased over time but remained low (<0.6 initiations per 100 person-months) in all years studied. Medication initiation was less common among those of Black or other race/ethnicity (HR 0.81 [95% CI 0.79-0.84] and HR 0.84 [95% CI 0.75-0.95], respectively) and decreased with increasing SDI (HR 0.96 [95% CI 0.96-0.97]). Initiation was higher in ASCVD than CHF (0.35 vs. 0.135 initiations per 100 person-months). Moderate (e.g., nephropathy, nonalcoholic fatty liver disease) but not severe (e.g., advanced chronic kidney disease, cirrhosis) comorbidities were associated with higher probability of medication initiation. CONCLUSIONS: Among older adults with T2D and either ASCVD or CHF, initiation of GLP1-RA or SGLT2i was low, suggesting a substantial deficit in delivery of guideline-recommended care or treatment barriers. Individuals of Black and other race/ethnicity and those with higher area-level socioeconomic deprivation were less likely to initiate these medications.
引用
- Cromer SJ, Lauffenburger JC, Levin R, et al. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Diabetes Care. 2023. PMID: 36383481. doi:10.2337/dc22-0383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。